Solid tumor program

Vaxiion is taking a novel approach to the treatment of solid tumors by designing products that simultaneously target the tumor and the tumor vasculature and is employing both the i-TNT™ and a-TNT™ platforms to accomplish this.

For example, a key integrin targeted by the beta1 integrin-targeting molecule invasin (a key element of the i-TNT™ platform) is the heterodimeric fibronectin receptor alpha5beta1  (α5β1) integrin. α5β1 integrin is well recognized as both a validated selective solid tumor cell and a selective tumor vasculature target and has been implicated in metastatic melanoma, pancreatic, colorectal, and non-small cell lung cancers. Oncology-related clinical trials have been or are being carried out by biotechnology and pharmaceutical companies with several α5β1 antagonists. Vaxiion is taking a novel approach by using the invasin protein to target α5β1 in order to deliver extremely potent payloads to tumors and tumor vasculature. 

A TNT™ product generated from either platform that selectively and effectively targets and kills tumor cells and the cells of the tumor vasculature irrespective of their proliferation, mutational, or drug resistance status, would have the potential to be marketed and sold for a wide variety of solid tumor indications with high unmet need.

Hematological tumor program

Vaxiion is also looking to improve upon the therapeutic battery available for hematological tumors, again leveraging both the i-TNT™ and a-TNT™ platforms to accomplish this. 

Vaxiion has prioritized hematological cancers based on the degree of the unmet medical need and on the technological capabilities of the respective TNT™ platform, and eAML (elderly acute myeloid leukemia) sits at the top of the list.